Physician profile
Vijay Singh
NPI 1174786297
$7,545.02
in general payments reported to CMS, 2019-2025
39 companies · $1,443 in 2025
The $1,443 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $785 · 2020: $225 · 2021: $302 · 2022: $856 · 2023: $2,121 · 2024: $1,813 · 2025: $1,443.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,222 · Education: $155.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,222.42 |
| Education | $154.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,408.09 | 2019-2025 | Rinvoq, Skyrizi |
| Amgen INC. | $949.39 | 2019-2025 | Enbrel, Tavneos, Krystexxa |
| Ucb, INC. | $779.23 | 2019-2025 | Cimzia, Bimzelx |
| Janssen Biotech, INC. | $620.08 | 2019-2025 | Tremfya, Simponi Aria |
| Ani Pharmaceuticals, INC. | $579.60 | 2022-2025 | Purified Cortrophin Gel |
| Astrazeneca Pharmaceuticals LP | $465.35 | 2021-2025 | Saphnelo |
| Novartis Pharmaceuticals Corporation | $461.69 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $398.76 | 2019-2025 | Orencia |
| Pfizer INC. | $383.27 | 2019-2025 | |
| Glaxosmithkline, LLC. | $286.01 | 2019-2024 | Benlysta |
| Horizon Therapeutics Plc | $95.32 | 2019-2023 | Krystexxa |
| Lilly USA, LLC | $87.69 | 2019-2024 | Taltz, Olumiant |
| Fresenius Kabi USA, LLC | $80.05 | 2023-2025 | Idacio |
| Genzyme Corporation | $79.31 | 2024-2025 | |
| Organon LLC | $79.02 | 2023-2025 | Hadlima, Renflexis |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vijay Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.